These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 35101649)
1. Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present). He X; Zhang H; Zhang Y; Ye Y; Wang S; Bai R; Xie T; Ye XY Eur J Med Chem; 2022 Mar; 231():114143. PubMed ID: 35101649 [TBL] [Abstract][Full Text] [Related]
2. Recent developments in catalysis and inhibition of the Jumonji histone demethylases. Sarah L; Fujimori DG Curr Opin Struct Biol; 2023 Dec; 83():102707. PubMed ID: 37832177 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a Highly Selective Cell-Active Inhibitor of the Histone Lysine Demethylases KDM2/7. Gerken PA; Wolstenhulme JR; Tumber A; Hatch SB; Zhang Y; Müller S; Chandler SA; Mair B; Li F; Nijman SMB; Konietzny R; Szommer T; Yapp C; Fedorov O; Benesch JLP; Vedadi M; Kessler BM; Kawamura A; Brennan PE; Smith MD Angew Chem Int Ed Engl; 2017 Dec; 56(49):15555-15559. PubMed ID: 28976073 [TBL] [Abstract][Full Text] [Related]
5. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Duan L; Perez RE; Calhoun S; Maki CG Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078 [TBL] [Abstract][Full Text] [Related]
6. Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy. Zhang L; Chen Y; Li Z; Lin C; Zhang T; Wang G Drug Discov Today; 2023 May; 28(5):103519. PubMed ID: 36754142 [TBL] [Abstract][Full Text] [Related]
8. JmjC Family of Histone Demethylases Form Nuclear Condensates. Vicioso-Mantis M; Aguirre S; Martínez-Balbás MA Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887017 [TBL] [Abstract][Full Text] [Related]
9. The catalytic domains of all human KDM5 JmjC demethylases catalyse N-methyl arginine demethylation. Bonnici J; Oueini R; Salah E; Johansson C; Schofield CJ; Kawamura A FEBS Lett; 2023 Apr; 597(7):933-946. PubMed ID: 36700827 [TBL] [Abstract][Full Text] [Related]
11. The role and prospect of lysine-specific demethylases in cancer chemoresistance. Song YQ; Yang GJ; Ma DL; Wang W; Leung CH Med Res Rev; 2023 Sep; 43(5):1438-1469. PubMed ID: 37012609 [TBL] [Abstract][Full Text] [Related]
12. Recent Progress in Histone Demethylase Inhibitors. McAllister TE; England KS; Hopkinson RJ; Brennan PE; Kawamura A; Schofield CJ J Med Chem; 2016 Feb; 59(4):1308-29. PubMed ID: 26710088 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation by histone demethylases in hypoxia. Hancock RL; Dunne K; Walport LJ; Flashman E; Kawamura A Epigenomics; 2015 Aug; 7(5):791-811. PubMed ID: 25832587 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of Protein Methyltransferases and Demethylases. Kaniskan HÜ; Martini ML; Jin J Chem Rev; 2018 Feb; 118(3):989-1068. PubMed ID: 28338320 [TBL] [Abstract][Full Text] [Related]
15. A scintillation proximity assay for histone demethylases. Yu W; Eram MS; Hajian T; Szykowska A; Burgess-Brown N; Vedadi M; Brown PJ Anal Biochem; 2014 Oct; 463():54-60. PubMed ID: 25010373 [TBL] [Abstract][Full Text] [Related]
16. Targeting histone demethylases as a potential cancer therapy (Review). Diao W; Zheng J; Li Y; Wang J; Xu S Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35801593 [TBL] [Abstract][Full Text] [Related]
17. The Emerging Significance of Histone Lysine Demethylases as Prognostic Markers and Therapeutic Targets in Head and Neck Cancers. Dorna D; Paluszczak J Cells; 2022 Mar; 11(6):. PubMed ID: 35326475 [TBL] [Abstract][Full Text] [Related]
18. Lysine Demethylation in Pathogenesis. Cao J; Yan Q Adv Exp Med Biol; 2023; 1433():1-14. PubMed ID: 37751133 [TBL] [Abstract][Full Text] [Related]